A brief BusinessWorld Online item touching on the oral Wegovy pill and Hers. Little detail was available beyond the headline.
Recap by typeshit. Full story at BusinessWorld Online.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
The writer cites a Gallup survey putting about 11 percent of Americans on GLP-1s and argues the real share is likely higher, and wants use discussed openly.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
Newsweek points to research showing patients can put lost weight back on quickly once they come off GLP-1 drugs.
Wegovy is semaglutide acting on GLP-1, while Mounjaro is tirzepatide acting on both GIP and GLP-1. A short social post breaks down the difference.
Loading…